STEM-Talk

Today we have Dr. Rudolph E. Tanzi, who is perhaps best known for co-discovering all three familial early-onset Alzheimer’s disease genes. In addition, Rudy’s lab was the first to use human stem cells to create three-dimensional human brain organoids and three-dimensional neural-glial culture models of Alzheimer’s disease, which became known as “Alzheimer’s-in-a-Dish.” These models were the first to recapitulate all three of the key pathological hallmarks of Alzheimer’s disease and have made drug screenings faster and cheaper.

Rudy is the director of the Genetics and Aging Research Unit as well as the director of the Henry and Allison McCance Center for Brain Health. Rudy is also co-Director of the Massachusetts General Institute for Neurodegenerative Disease at Massachusetts General Hospital and serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.

Rudy has published more than 700 research papers and is one of the top 50 most cited neuroscientists in the world. He is author of “Decoding Darkness,” and a co-author of two books with Deepak Chopra, “Super Brain” and “The Healing Self.”

Show notes:

[00:03:18] Ken opens the interview mentioning that Rudy began playing the accordion when he was just seven years old. Ken goes on to ask Rudy about the time his father gave him a Jimmy Smith album and some advice.

[00:05:51] Ken mentions that, in addition to Rudy’s musical talents, he was also interested in science growing up. Ken asks about Rudy’s participation in the Westinghouse Science Talent Search and what that experience was like.

[00:07:09] Ken asks Rudy about growing up in Cranston, Road Island.

[00:08:39] Rudy talks about how he ended up at the University of Rochester after high school.

[00:09:51] Ken mentions that both Rudy’s grandfather and father passed away at the age of 45. Ken asks Rudy if this played a role in his pursuit of a career in genetics research.

[00:10:57] Rudy explains how he chose Harvard Medical School for his Ph.D.

[00:12:47] Ken pivots to ask Rudy about his time working with Jim Gusella in the early 80’s at Mass General, where they were the first to ever find a disease gene. Family studies at the time had shown that the Huntington’s disease gene was linked to a polymorphic DNA marker. Rudy talks about this discovery and how the chromosomal localization of the Huntington’s disease gene was the first step in using recombinant DNA technology to identify the primary genetic defect in this disorder.

[00:16:07] Ken asks Rudy about his work in 1987, when he discovered the first Alzheimer’s gene, recombinant DNA technology, which causes the production of amyloid. Ken goes on to explain that mutations in the APP gene can cause a rare form of early onset Alzheimer’s. Rudy talks about the paper that came out in “Science” that detailed this discovery.

[00:18:38] Rudy discusses his personal philosophy and approach to research.

[00:19:43] Ken mentions that in Rudy’s book, Decoding Darkness, he writes that few nightmares on Earth can compare to Alzheimer’s disease. Ken asks Rudy to talk more about this book.

[00:21:50] Ken explains that in the same way our physical capabilities will suffer some form of decline with age, it is also expected that we have some decline in memory and cognitive ability as we age as well. However, Ken goes on to say that when people begin to experience age-related memory lapses, it can lead to a lot of anxiety about their genetic predisposition to Alzheimer’s. Ken asks Rudy to talk about the lifestyle factors that play into whether someone predisposed to develop Alzheimer’s can stave off or avoid disease development.

[00:26:09] Ken explains that aging appears to intensify when people stop challenging themselves with new things. Given this, Ken asks Rudy what his thoughts are on challenging our brains as they age to protect our cognitive abilities.

[00:29:08] Ken asks Rudy about the principal advances in Alzheimer’s research that have occurred over the past few decades. He also asks Rudy for his thoughts on the biggest and most important mysteries that remain regarding Alzheimer’s.

[00:34:48] Ken brings up one of Rudy’s papers, published in 2014, which they successfully recapitulated amyloid-β and tau pathology in a single 3D human neural cell culture system. Ken goes on to mention that this paper had a huge impact in the field of research, and even landed Rudy a spot on Time Magazine’s 100 most influential people list.

[00:38:57] Ken mentions that in 2019, Rudy published another influential paper, which investigated the crosstalk between microglial receptor genes CD33 and TREM2. Ken explains that these two genes have been associated with an increased risk of Alzheimer’s disease, and that Rudy has referred to them as yin and yang to each other. Ken asks Rudy to elaborated on this concept.

[00:43:00] Ken pivots to discuss Rudy’s paper that was published last year and which the press somewhat misleadingly reported on. Ken explains that physical exercise has been shown to reduce amyloid beta in various Alzheimer’s models, but it is imperfectly associated with amyloid burden in humans. Ken goes on to explain that Rudy’s paper demonstrated, for the first time, a cellular and molecular mechanism by which exercise induced irisin attenuates amyloid beta pathology.

[00:46:27] Ken mentions that Rudy is currently writing a new book and mentions that some of Rudy’s previous books have been co-authored with Deepak Chopra. Ken asks how Rudy and Deepak came to work together.

[00:51:24] Ken asks, given the complex nature of Alzheimer’s and the many components that contribute to the pathology, if there is a way to organize all we know about Alzheimer’s in a straight-forward way.

[00:58:19] Ken asks if there are any particularly promising FDA approved drugs or nutraceuticals for stopping the production of amyloid.

[01:00:16] Ken asks if Rudy gets questions regarding which drugs and supplements screened have shown the most promise.

[01:03:33] Ken closes the interview by asking how he manages to be such a prolific scientist. Rudy has published more 700 papers while also having a lifetime of playing music with rock bands, working with sports teams and publishing New York Times best sellers.

Links:

Rudy Tanzi bio

Learn more about IHMC

STEM-Talk homepage

Ken Ford bio

Ken Ford Wikipedia page

Our guest today is Dr. Anurag Singh, the chief medical officer at Timeline Nutrition, a Swiss life-science company that focuses on ways to improve mitochondrial and cellular health. Anurag is particularly known for his research into the gut metabolite, urolithin-A, which has been shown to improve muscle strength, protect immune systems and optimize mitochondrial efficiency.

Anurag is an MD in internal medicine with a Ph.D. in immunology. He has led more than 50 randomized clinical trials, many of them focusing on urolithin-A over the past decade.

In today’s episode we talk to Anurag about his investigations into urolithin-A and the role it plays as a postbiotic that enhances mitochondrial function. Foods that contain the polyphenols needed to produce urolithin-A include pomegranates, strawberries, raspberries and walnuts.

Show notes:

[00:02:48] Marcas starts the interview by mentioning that Anurag grew up in India, in Lucknow, and asks what Anurag’s childhood was like.

[00:03:56] Marcas follows up, asking Anurag what he was like as a kid, given the competitive environment he grew up in.

[00:04:47] Ken asks Anurag if it is true that, at an early age, his parents noticed he was gifted in biology and encouraged him to think about pursuing medical school.

[00:05:47] Ken asks if Anurag started medical school at only 18 years of age.

[00:06:28] Marcas explains that Anurag went to India’s Armed Forces Medical College for training in internal medicine and asks if it is true that this is one of India’s top medical schools.

[00:07:07] Marcas explains that it is typical for graduates from the India Armed Forces Medical College to serve a few years in the Indian army after graduation. Marcas asks Anurag to tell the story of how he was able to go to the U.S. post-graduation rather than serving time in the army.

[00:08:00] Ken asks if Anurag’s interest in medical research led him to pursue a Ph.D. in immunology.

[00:08:56] Ken asks Anurag what his Ph.D. research was on.

[00:09:37] Marcas mentions that in 2009, Anurag accepted a position at Nestlé at a time when the company was entering into the space between food and pharma. Marcas asks Anurag how this move came about.

[00:11:20] Ken explains that Anurag quickly became medical director at Nestlé and started initiating clinical trials around food and allergies, as well as research on aging and how the immune system declines with age. Ken asks Anurag to explain what his time at Nestle was like.

[00:12:53] Marcas mentions how the shift from practicing physician to research scientist is an interesting course and asks Anurag to talk about a mentor who gave him the advice that led to his career shift.

[00:13:55] Ken mentions that in 2014 Anurag joined a Swiss company, Amazentis, as chief medical officer, and later became the lead for their medical and clinical research strategies. Ken asks Anurag to talk about the company and the work he does.

[00:15:00] Ken asks Anurag to describe the relationship between Amazentis and Timeline.

[00:15:42] Marcas asks Anurag to elaborate on his biotech approach to nutrition science, and how hard biology is used in his nutritional approaches at Amazentis.

[00:18:02] Marcas asks Anurag to give listeners an overview of the function and importance of mitochondria.

[00:19:15] Ken asks Anurag if there are any other benefits to good mitochondrial health, other than an increased energy supply.

[00:20:24] Ken asks Anurag to define the terms “mitochondrial biogenesis” and “mitophagy.”

[00:22:13] Marcas pivots to discuss age-related frailty and healthspan, specifically bringing up a study Anurag conducted on a Dutch population comparing active seniors to sedentary seniors.

[00:25:09] Ken mentions that Marcas likes to refer to exercise as medicine, given its potent effects on a wide variety of biomarkers. Ken asks Anurag to discuss the importance of exercise.

[00:26:59] Following up on the Dutch study, Marcas mentions that there is an explosion of research into healthspan, resilience, and even lifespan, and asks Anurag to discuss the core principles of healthy aging.

[00:29:14] Ken asks Marcas to give a brief aside as to the capacity, capabilities, and aims of IHMC’s new Healthspan Resilience and Performance complex.

[00:31:36] Ken mentions that poor metabolic health continues to be a growing global issue. Ken asks Anurag to share his thoughts on the issue.

[00:33:25] Marcas circles back to Anurag’s work at Timeline investigating natural compounds that target mitochondrial health. Marcas notes that Anurag and his colleagues found that urolithin-A outperformed every other molecule tested with respect to mitochondrial health. Urolithin-A is a natural compound produced by gut bacteria from metabolizing ellagitannins and ellagic acid, complex polyphenols found in foods such as pomegranates berries and nuts. Marcas asks Anurag to explain what these compounds are in detail.

[00:35:25] Marcas asks if there are lifestyle changes one can make to improve their gut microbiome population to increase how much urolithin A one can pull from food sources.

[00:37:07] Ken asks, assuming the hypothetically perfect microbiome and the perfect ellagitannin conversion, if it is possible through diet alone to produce enough urolithin A to observe considerable benefit.

[00:38:51] Marcas asks if any factors, other than chronic antibiotic use, have been shown to negatively affect the gut microbiome and its ability to produce urolithin-A.

[00:41:09] Marcas moves on to discuss Anurag’s 2016 paper titled “Urolithin-A induces mitophagy and prolongs lifespan in c-elegans and increases muscle function in rodents” Marcas asks Anurag to discuss the origins of this paper and the impact of its findings.

[00:44:18] Ken asks if the professor that Anurag partnered with on his 2016 paper ever investigated rapamycin as opposed to metformin.

[00:45:08] Ken asks if the primary mechanism of action regarding urolithin-A’s effect on mitophagy is known or if we have only seen a strong association with other mechanisms of mitophagy and autophagy.

[00:46:14] Marcas explains that in the progression of aging and a sedentary lifestyle, there is a decline in a cell’s ability to eliminate dysfunctional elements through autophagy and mitophagy. This decreased capacity specifically in skeletal muscle has been associated with poor muscle health and quality in older adults. Marcas asks about a 2019 paper Anurag wrote that detailed the results of his first human clinical trial in which he administered urolithin-A to sedentary but otherwise healthy adults.

[00:49:35] Marcas mentions that exercise also activates mitophagy, and asks if there are any key cellular, or mechanistic, differences between exercise and urolithin-A in their effects on mitochondrial health.

[00:50:49] Ken mentions that Anurag’s research on urolithin-A led to the development of Mitopure, which is the first postbiotic nutrient that has been shown to trigger mitophagy by targeting cellular decline. Ken goes on to mention that in 2022, Anurag published the paper “Urolithin-A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle aged adults” in which subjects were given oral doses of Mitopure. Ken asks Anurag to discuss this paper and its findings.

[00:54:37] Ken asks Anurag to discuss the specific contents of each package of Mitopure.

[00:56:19] Ken mentions that many therapies targeting mitochondrial health seem to only be effective when there is some defect or problem with the mitochondria. Ken asks Anurag’s why it seems that mitochondrial therapies can only return mitochondrial functioning to baseline rather than increase performance above baseline.

[00:58:15] Maras asks Anurag if he thinks that Mitopure is best used as a supplement to healthy lifestyle choices such as exercise, rather than a replacement for them.

[00:59:42] Ken pivots to talk about the sources of urolithin A, one of which being Iberian pigs, which consume a diet almost exclusively of acorns, which are rich in ellagitannins. Ken asks if the urolithin-A in Iberian pigs can be found in the ham meat itself.

[01:01:45] Marcas mentions Anurag’s paper published in the journal Aging Cell, which showed that Mitopure supplementation had potential to improve mitochondrial functioning in human cartilage. In this study, Anurag demonstrated that Mitopure supplementation for eight weeks, protected against osteoarthritic disease progression. Marcas asks Anurag to talk about this potential.

[01:04:03] Ken mentions that much of the research on urolithin-A has been conducted on its effects on skeletal muscle; however, urolithin-A also would be expected to have effects on other mitochondrially dense tissue as well. Ken asks if there has been any research on urolithin-A’s effects on tissues like liver or cardiac tissue.

[01:06:23] In response to Anurag mentioning the Buck institute’s research with urolithin-A, Ken mentions that we discussed urolithin-A at length with Buck institute researcher Julie Andersen on episode 118.

[01:07:34] Moving on to Anurag’s current research, Marcas asks about a randomized controlled trial in collaboration with the Buck Institute to see if urolithin-A can improve the immune health of middle-aged adults by improving mitochondria health.

[01:11:17] Ken asks about a recently completed randomized controlled trial looking at elite runners to determine whether overtraining induces mitochondrial dysfunction and whether urolithin-A has an impact on muscle recovery.

[01:14:40] Ken mentions that with all the interest growing in urolithin-A, there is an explosion of supplements on the market, which one cannot know the true composition or quality of. Ken asks Anurag if he has any advice for consumers who might want to try urolithin-A.

[01:17:28] Marcas closes the interview asking Anurag how he likes to spend his free time.

Links:

Anurag Singh bio

Anurag Singh ResearchGate

Learn more about IHMC

STEM-Talk homepage

Ken Ford bio

Ken Ford Wikipedia page

Marcas Bamman bio

Few people know as much about inflammation and neuroscience as Dr. Kevin Tracey does.

In this episode of STEM-Talk, we learn much from Tracey, who was the first to identify the inflammatory reflex, a physiological mechanism that regulates the body’s immune response to injury and invasion.

He is a neurosurgeon, a pioneer in bioelectrical medicine and president and CEO of the Feinstein Institutes for Medical Research in Manhasset, N.Y. The conversation in this episode covers a career spent working on “producing tomorrow’s cures today” in the treatment of inflammatory diseases, including:

[00:03:04] Dawn asks Kevin to tell the story of how he developed an interest in science that evolved into him becoming a neurosurgeon.

[00:04:56] Dawn mentions that Kevin was a curious youth and asks if it is true that after getting his first car, Kevin removed the entire engine because he wanted to better understand how to do a valve job.

[00:06:33] Ken mentions that after Kevin graduated from high school, he enrolled in Boston College where he earned a bachelor’s degree in chemistry. Ken explains that Kevin went to Boston University Medical School for his M.D. and asks Kevin about the transition.

[00:08:41] Ken asks if it is true that during Kevin’s first year at medical school his classmates had better luck finding him on the golf course than in the classroom.

[00:10:42] Dawn asks Kevin about his transition from medical school to the neurological surgery training program at New York Hospital, home of the Cornell University Medical College.

[00:13:11] Dawn pivots to talk about sepsis, which kills more than 350,000 people annually. She asks Kevin to discuss his tragic story of treating a patient with sepsis as a young neurosurgeon and how that changed the trajectory of his career.

[00:16:38] Ken explains that since the aforementioned incident, Kevin has focused on determining why septic shock occurs. Ken refers to a Ted Talk of Kevin’s in which he says, “good science begins with hard questions.” Ken asks Kevin to elaborate on this point.

[00:20:49] Dawn mentions that Kevin often describes himself as a brain surgeon who is fascinated by inflammation. Dawn asks Kevin how he responds when people ask him what inflammation is.

[00:22:29] Ken follows up by explaining that in 1987 Kevin made progress investigating inflammation with his discovery of tumor necrosis factor (TNF), which contributed to a new class of drugs for inflammatory and autoimmune diseases. Ken asks Kevin to discuss this discovery.

[00:25:56] Dawn mentions that in the late ‘90s, Kevin made another discovery that allowed him and his colleagues to merge neuroscience and immunology. Before getting into that discovery, Dawn asks Kevin to explain how humans have simple reflex circuits that harmonize the activity of our organs. She also asks him to talk about Charles Sherrington’s Nobel Prize-winning research, which laid the groundwork for contemporary neuroscience by showing how reflex circuits are the building blocks of our nervous system.

[00:29:50] Ken asks Kevin to elaborate on what monoclonal antibodies are, what disorders they can be used to treat, and what their potential benefits and downsides are.

[00:33:10] Dawn asks Kevin to talk about the discovery he made in the late 1990s, while studying the possibility of blocking TNF during a cerebral infarction or stroke by injecting a molecule that he and his colleagues developed directly into the brain.

[00:35:59] Ken mentions that after this discovery, Kevin started looking into well-established methods in neuroscience, such as those that link specific areas of the brain to specific cognitive functions and asks Kevin to discuss this research.

[00:39:45] Dawn explains that the insight that discrete brain regions control specific behaviors led Kevin to postulate that cutting the circuits connecting the brain and organs could reveal the identity of specific areas that control TNF. Dawn asks Kevin to walk through how he investigated this hypothesis.

[00:44:22] Ken asks Kevin to give an overview of the functions of the vagus nerve.

[00:46:00] Ken mentions that our show notes will provide a link to a short video that maps out the vagus nerve in detail. Ken goes on to mention that after Kevin looked into the relationship between TNF and the vagus nerve, he theorized that the TNF off signal from the vagus nerve completes a nerve circuit between the brain and the immune system. This finding had broad implications, and Ken asks Kevin to elaborate on them.

[00:50:57] Dawn mentions that Kevin wrote an article in 2002 for the journal Nature titled “The Inflammatory Reflex”, which emphasized the basic neural pathway that research had identified which reflexively monitors and adjusts the inflammatory response. Dawn goes on to mention that Kevin coined the term “inflammatory reflex” to describe how the nervous system monitors and controls the circuit to prevent the immune system from becoming overactive or underactive. Additionally, Kevin proposed in this article that it might be possible to activate neural anti-inflammatory mechanisms using small molecules to initiate signals in the central nervous system. Dawn asks Kevin to give an overview of the key insights into the inflammatory reflex he discussed in that article.

[00:54:15] Ken comments on the monumental importance of this paper to the field of neuro-immunology, and the treatment of inflammatory diseases, and asks Kevin what the response to this paper was.

[00:57:30] Dawn explains that Kevin has proposed that a dysregulated inflammatory reflex can lead to toxicity, tissue damage, and the presence of cytokines. It also can lead to miscommunication among cytokines leading to potential complications with autoimmune diseases. Dawn asks Kevin to talk about the process of testing this theory.

[01:00:54] Dawn asks Kevin about a sketch he drew while having lunch, which laid out how treating inflammatory diseases using a bioelectronic device might be possible.

[01:05:18] Ken pivots to talking about an influential 2016 paper that Kevin wrote on how the stimulation of the vagus nerve targeted the inflammatory reflex.

[01:08:23] Ken asks if there are any adverse effects suspected or identified for stimulating the vagus nerve in humans.

[01:12:02] Ken mentions that in writing about the vagus nerve Kevin has often talked about how the vagus nerve can get “out of tune.” Ken asks Kevin to explain how this occurs and what it means.

[01:14:41] Dawn mentions a study that Kevin spearheaded, which found that the dorsal motor nucleus is an important brain stem locus controlling anti-inflammatory signals and the inflammatory reflex. Dawn asks Kevin to discuss this study and how it was the first to demonstrate that neurons in the brain stem nuclei control the production of TNF.

[01:17:51] Dawn asks about a study Kevin and his colleagues conducted that looked at the use of an implanted vagus nerve stimulator in a small group of patients with Crohn’s disease.

[01:20:55] Ken asks Kevin what advances in bioelectronic medicine he envisions in the next decade.

[01:23:23] Ken mentions that the pharmaceutical industry is likely keeping a close eye on the development of bioelectronic medicine.

[01:24:25] Dawn mentions that Kevin is the president and CEO of the Feinstein Institute for Medical Research at Northwell Health, which has 50 research labs, and more than 5,000 researchers and staff on board. Dawn asks Kevin to talk about this research center and the range of work that goes on there.

[01:27:29] After mentioning that Kevin holds 120 U.S. patents, Ken asks Kevin about his ongoing tinkering and development of inventions.

[01:30:22] Dawn asks Kevin, with all the work he has on his plate, if he still finds time to golf.

Links:

Kevin Tracey bio

Feinstein Institutes for Medical Research

Learn more about IHMC

STEM-Talk homepage

Ken Ford bio

Ken Ford Wikipedia page

Dawn Kernagis bio

In today’s Ask Me Anything episode, Ken and Dawn answer a wide range of questions that cover:

[00:02:38] Dawn opens the episode with a question for Ken about the FDA’s recent approval of a neural implant device which is touted as a means of allowing people with degenerative neuromuscular disease, or spinal-cord injuries, to interface with external technology via neural signals. The listener asks Ken for his insights into what is being called “brain-computer interface technologies.”

[00:05:44] A listener asks Ken if he has a favorite science-fiction writer, or if there is a particular sci-fi series/story that really moves him.

[00:08:48] Multiple listeners ask Ken about a paper recently published titled: “APOE 4 Homozygosity Represents a Distinct Genetic Form of Alzheimer’s Disease.” Listeners ask if it is true that people with two copies of APOE4 allele are certain to develop the disease.

[00:19:30] A listener asks Ken about his time on the National Security Commission on Artificial Intelligence. The commission issued its report five years ago with specific recommendations on how the government should prepare for and defend against the national security implications of AI. Ken shares his thoughts on the implementation of the commission’s recommendations.

[00:21:16] A listener asks Dawn about her collaboration with Dr. Jeff Iliff that looked at a potential approach to optimizing glymphatic clearance for people with acute or chronic sleep deprivation.

[00:27:10] A listener asks Ken why more gyms and physical therapy centers don’t have blood flow restriction devices (BFR) available for their clientele, given that studies have shown that BFR improves strength and muscle mass in both young and older adults. (Two STEM-Talk episodes that cover blood-flow restriction include episode 34 and episode 161.

[00:28:38] A listener asks Ken for his thoughts on AI given the recent developments in the field, particularly in the realm of Generative AI, with programs like Chat GPT becoming a household name. The listener mentions that one of their friends thinks that AI is about to peak, and another says that AI is just getting warmed up.

[00:37:00] A listener writes that they are astounded at how many disorders can be treated with a ketogenic diet and mentions that they themselves have difficulty with a ketogenic diet. Instead, the listener eats low-carb diet and asks if the benefits of a low-carb, non-ketogenic diet are similar to a ketogenic one.

[00:38:19] A listener asks if Ken could talk about carotid scans and if this is a test that those with high LDL should consider getting.

[00:40:17] A 72-year-old listener explains how they structure their daily exercise routine between resistance and endurance training. The listener asks Ken whether they should focus more on resistance training as they are beginning to lose strength, and if so, how they should implement that given their age and the increasing risk for injury.

[00:45:51] To wrap up this episode, a listener asks Ken if he has any new annoyance that he would like to share, as he did in 2022, when he noted his disdain for the phrase “new normal” and the prevalence of cellphone addiction.

Links:

Learn more about IHMC

STEM-Talk homepage

Ken Ford bio

Ken Ford Wikipedia page

Dawn Kernagis bio

Today Dr. David LeMay steps in to co-host with Dr. Ken Ford for our interview with Dr. Charles Serhan. Charles is a Harvard professor best known for his discovery of specialized pro-resolving mediators. SPMs are molecules that can activate the natural resolution of inflammation and help people avoid anti-inflammatory drugs. The discovery of SPMs spurred a paradigm shift in our understanding of inflammation and human disease.

Charles is the Simon Gelman Professor of Anesthesia at Harvard Medical School and the director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital. He also is a co-director of the Brigham Research Institute.

David, who was our guest on Episode 69 of STEM-Talk, is a sports medicine and rehabilitation physician with a Pensacola, Florida practice that focuses on lifestyle and performance medicine. He also is a visiting research scientist here at IHMC.

Show notes

[00:03:33] David opens the interview mentioning that Charles grew up in New York City with a passion for music. David explains that Charles learned to play the vibraphone in junior high and played professionally for a year before going to college. David asks Charles why he decided to pursue science instead of music.

[00:04:22] Ken asks Charles what kind of vibraphone he plays.

[00:06:02] Ken asks, aside from the desire to help people, if there was something particular about studying science that Charles really enjoyed.

[00:06:45] David asks about Charles’ experience at the State University of New York at Stonybrook studying biochemistry and immunohistochemistry.

[00:07:16] David asks if there was any carry over of skills for Charles from his career in music to his career in science.

[00:08:16] Ken mentions that after Charles earned his bachelor’s degree, one of his professors persuaded him to go to New York University for a master’s and Ph.D. Ken also mentions that at the time Charles worked in the lab of Gerald Wiseman at Woods Hole Marine Biological Laboratory and asks about that experience.

[00:12:37] David asks if this experience led Charles to a focus on neutrophil membrane remodeling for his Ph.D.

[00:13:59] David asks Charles if it was at the Karolinska Institute where he met his future wife.

[00:14:38] Ken asks Charles about one of his mentors, Michael Heidelberg, who gave Charles advice about how to be a good scientist.

[00:17:13] David explains that in the 1990’s Charles discovered Specialized Pro-Resolution Mediators and has since pioneered a new field on the utility of SPMs for a variety of inflammatory diseases.

[00:25:01] Ken backs up to ask Charles what drew him to study inflammation in the first place and how that led him to do more research on the subject than any other scientist.

[00:26:26] David asks Charles to touch on some different types of inflammation that the body experiences.

[00:35:12] Ken asks Charles about how a trip to Asia during which he developed a hole in his intestines, resulted in first-hand experience on the importance of controlling inflammation.

[00:41:00] David asks if Charles was taking any non-steroidal anti-inflammatory medications when he developed peritonitis.

[00:41:53] David asks Charles to explain what non-steroidal anti-inflammatory medications do to the healing process.

[00:45:35] David brings up a recent discovery in animal models that as animals age, their ability to produce resolution mediators declines, possibly contributing to the loss of muscle mass with age.

[00:48:09] Ken asks Charles to talk about the explosion of research into the potential therapeutic applications of SPMs in the treatment of a variety of chronic diseases known to be driven in part by chronic inflammation.

[00:51:06] David asks Charles to explain the differences between resolvins, protectins, and maresins, as well as what role each plays in the healing process.

[00:56:04] Ken mentions a review article that Charles published in 2017 in the Journal of Molecular Aspects of Medicine, which looked at SPMs and their capacity to change pharmacology through resolution physiology.

[01:00:22] David asks Charles to explain the difference between inflammation and resolution.

[01:03:13] Ken asks Charles to give an overview of the research he is currently conducting at the Serhan Laboratory.

[01:05:50] David asks Charles about a paper he published last year in the Proceedings of National Academy of Sciences titled: “Resolvin D1 Prevents Injurious Neutrophil Swarming in Transplanted Lungs.” This provided insights for therapeutically enhancing pro-resolution pathways to minimize early leukocyte mediated tissue injury and promote healing following transplantation.

[01:08:43] David asks Charles if the aforementioned use of Resolvin D1 works for ailments such as ischemic stroke or ischemic myocardium after a cardiac event. Charles brings up a paper by Gabrielle Fredman that explored the use of resolvins to reduce inflammation in atherosclerosis.

[01:13:10] David mentions that Charles has three children, two of whom are in the military and asks for Charles’ thoughts on the use of SPMs in military populations.

[01:17:04] David asks Charles if there might be any protective effects of taking SPMs prior to or during exposure to extreme environments.

[01:17:48] Ken comments on Charles’ use of the phrase “nutritional armor,” coined by Joe Hibbeln. Charles talks about his experience working with Joe over the years.

[01:19:00] Ken recounts an experience when he was a member of the Defense Science Board and invited Joe Hibbeln to present his nutritional armor concept to the Board.

[01:22:05] David mentions that for the sports science world, recovery is a big focus. David asks if resolution is a more appropriate way to approach this issue than traditional anti-inflammatory interventions.

[01:23:33] David follows up asking Charles what the role of sleep is in resolution.

[01:24:57] David shares some of his experience using SPMs in his practice, and Ken mentions his own personal use of SPMs. Charles discusses how SPMs are derived and the importance of supplementation.

[01:31:04] Ken mentions that there were two books that Charles found very influential in his early career, “The Art of Scientific Investigation,” and “Men Like Gods.” Ken asks how these books impacted Charles, and if he still recommends them to young scientists and graduate students.

Links:

Charles Serhan bio

Learn more about IHMC

STEM-Talk homepage

Ken Ford bio

Ken Ford Wikipedia page

David LeMay bio

Dave Feldman is the founder of the Citizen Science Foundation and is known for his research into the ketogenic diet. Dave is a software engineer by training who embraced a ketogenic diet to avoid his progression toward type 2 diabetes. he joins us on this episode of STEM-Talk to share that journey.

After undertaking the high-fat/low-carbohydrate diet, Dave’ LDL cholesterol spiked. Dave used his training as an engineer to start learning everything he could about cholesterol and lipids. What he learned led him to create the website Cholesterol Code, a research hub for information and emerging data on cholesterol, particularly in the context of a low-carbohydrate lifestyle.

Dave’s Citizen Science Foundation is designed to support projects and research that promote collaborative efforts across multiple disciplines, both in and outside formal scientific institutions.

Show notes:

[00:02:53] Dawn opens the interview asking Dave what he was like as a kid.

[00:03:44] Dawn mentions that Dave divided his time as a child between Denver and Wichita due to his parents’ divorce and asks Dave what the best part of his childhood was.

[00:04:28] Ken mentions that Dave has described both his parents as graphic artists and Bohemian, “hippie spirit” types. Ken asks what he learned from them that fueled his interests and goals.

[00:05:46] Ken asks about Dave’s first computer, which was a Commodore 64, as well as his early experience with computers.

[00:08:50] Dawn mentions that Dave’s interest in computers came in a time before the internet and asks what he learned about computing in those days.

[00:10:51] Dawn explains that since Dave grew up in the 1980s, there was not much in the way of computer science curriculum in schools and asks Dave how he supported his interest in programming.

[00:12:33] Ken asks Dave about how self-directed learning has been a theme throughout his whole life.

[00:14:35] Dawn asks Dave about his childhood hobbies, including running and competitive storytelling.

[00:17:01] Ken asks how Dave’s experiences in forensic debate in high school helped his career later in life.

[00:18:56] Dawn mentions that Dave initially attended film school and asks if it is true that Dave’s side hustle of doing contract software work overtook his original plan to graduate.

[00:20:49] Dawn asks about Dave’s experiences working in the game platform development business in Las Vegas, as well as what these experiences taught him.

[00:22:23] Ken asks Dave about a “the piece of paper” that Dave says changed his life in 2015.

[00:28:58] Ken follows up, asking Dave if he checked his LDL-P or his ApoB at the same time as his cholesterol levels.

[00:30:37] Ken mentions that he knows some people that when consuming a ketogenic diet did not see a substantial increase in LDL-C, but did experience a substantial elevation of LDL-P.

[00:35:03] Ken pivots to discuss a paper that Dave and others published in Current Developments in Nutrition in 2022 titled: “Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for Lean Mass Hyper-Responder Phenotype.” Ken asks Dave to describe what it means to be a lean mass hyper-responder.

[00:40:19] Ken mentions his caution against the term lean mass hyper-responder, as it is unclear what “lean mass” refers to in this case. Ken goes on to say that while the lean mass hyper-responder phenotype can be objectively measured in terms of LDL, HDL and triglyceride levels, the lean mass aspect is often measured in these studies with BMI, which is unable to measure body composition. Ken asks Dave what his thoughts are on this and if he would like the possibility of moving away from BMI and towards DEXA scans.

[00:43:37] Ken mentions that Dave’s original article describing the lean mass hyper-responder phenotype has received a lot of response from individuals claiming to fall into that category. While it is difficult to get a precise estimate of the population that fits this phenotype, Ken asks Dave what he thinks the percentage might be.

[00:47:33] Dawn asks about the case report published in Frontiers in Endocrinology in 2022 titled: “Case Report: Hypercholesterolemia, Lean Mass Hyper-Responder Phenotype Presents in the Context of a Low Saturated Fat Carbohydrate-Restricted Diet.” This paper highlights the case of a hyper-responder who adopted a ketogenic diet to manage ulcerative colitis.  

[00:49:38] Ken asks how long the subject of the case report was on an extremely low-carb diet.

[00:50:48] Ken asks Dave, given that cholesterol levels and lipoproteins are remarkably elevated in lean mass hyper-responders, what he thinks the cumulative cardiovascular implications over an extended period might be.

[00:56:19] Dawn turns to discuss Dave’s 2022 paper on the Lipid Energy Model, titled: “Lipid Energy Model: Reimagining Lipoprotein Function in the Context of Carbohydrate Restricted Diets,” asking him to expound on the concept and its significance.

[00:59:02] Ken remarks on the extraordinarily fast review process for this paper on the Lipid Energy Model, explaining that the paper went through submission, review, revision, acceptance and publishing in 30 days.

[01:00:49] Dawn shifts to ask about a 2023 study by Dr. Isabella Cooper in Frontiers in Endocrinology titled: “Thyroid Markers and Body Composition Predict LDL Cholesterol Change in Lean Healthy Women on a Ketogenic Diet: Experimental evidence for the Lipid Energy Model.”

[01:02:48] Ken asks Dave about his journey to self-fund research through crowdfunding, for which he founded a 501c3 non-for-profit, which in 2019 was named the Citizen Science Foundation. Ken asks Dave what challenges he faced in this endeavor.

[01:05:47] Ken asks Dave to describe how he came to partner with the Lundquist institute at UCLA.

[01:08:33] Ken asks what the state of the Citizen Science Foundation is now, and if it has any projects that it is currently funding.

[01:09:57] Ken asks Dave how he sees the foundation evolving in the future and how he would like it to evolve.

[01:11:50] Dawn asks Dave about a study he and his team have just completed on 100 lean mass hyper-responders who received a CT Angiogram to establish baseline coronary artery status, and then a second scan a year later. Dawn asks Dave to discuss the findings of this study in terms of atherosclerotic plaque in the hyper-responder group as compared to the Miami Heart Study group, as well as the overall findings of the study.

[01:17:36] Ken follows up, asking if the results of the aforementioned study will be published soon.

[01:17:54] Dawn asks Dave about the documentary he is working on.

[01:19:53] Dawn closes the interview asking Dave why The Usual Suspects by Brian Singer is his favorite film.

Links:

Dave Feldman bio

Learn more about IHMC

STEM-Talk homepage

Ken Ford bio

Ken Ford Wikipedia page

Dawn Kernagis bio

Dr. Alessio Fasano, who is considered the world’s leading expert in celiac disease and gluten-related disorders, returns for his second appearance on STEM-Talk. Although just 2 million Americans have celiac disease, an estimated 20 million Americans suffer from gluten sensitivity.

Alessio is a professor and director of the Mucosal Immunology and Biology Research Center at Massachusetts General Hospital. In addition to celiac disease and gluten-related disorders, Alessio’s research is also focused on the microbiome, intestinal permeability and autoimmune disorders, which he discussed in his first interview on STEM-Talk, episode 20.

Since Alessio’s first appearance on STEM-Talk in 2016, he has published two books, “Gluten Freedom” and “Gut Feelings: The Microbiome and Our Health,” which we discuss in today’s interview. We also talk to Alessio about an exciting new project that’s bringing together an international consortium of researchers and scientists for a long-term study that will follow infants who are genetically at risk of developing celiac.

Alessio is a researcher and physician who wears many hats. He is the director of the Center for Celiac Research and Treatment and chief of the Division of Pediatric Gastroenterology and Nutrition at Mass General Hospital. He also is a professor of pediatrics at Harvard Medical School and a professor of nutrition at Harvard’s T.H. Chan School of Public Health.

Show notes:

[00:03:58] Marcas opens the interview welcoming Alessio back to STEM-Talk, mentioning that since his last appearance he has written two books: Gluten Freedom and Gut Feelings: The Microbiome and Our Health. Marcas asks Alessio how he became interested in pediatrics and gastroenterology.

[00:05:42] Ken mentions that Alessio moved to the U.S. in the 1990s and spent 20 years in Maryland at the Center for Vaccine Development in Baltimore. Ken goes on to mention that while Alessio was there, he founded The Center for Celiac Research in 1996, and in 2003, Alessio accepted an offer to join Massachusetts General Hospital. Ken asks how that move came about.

[00:08:53] Marcas asks about Alessio’s early career working on cholera, where he discovered the zonula occuldens toxin, the bacteria that causes cholera. Marcas asks Alessio to talk about this finding and the insights he gleaned from it.

[00:16:03] Ken asks about Alessio’s discovery of zonulin, which is the molecule that modulates gut permeability in humans. Ken asks Alessio to share how this discovery led him to investigate celiac disease, which is triggered by gluten.

[00:20:25] Ken asks Alessio what his thoughts are on why the medical community, historically, has not taken celiac disease seriously.

[00:24:08] Marcas mentions that as we age, there is evidence that the gut becomes leakier, which is highly related to chronic inflammation. Marcas asks Alessio whether this happens to the gut over time due to diet and lifestyle rather than the typical aging process.

[00:28:45] Ken mentions that there has been an increase in the diagnosis of celiac disease. Ken asks Alessio if that is due to an actual increase in the prevalence of the disease, or is it tied to a growing appreciation that clinicians have now for the disease?

[00:29:32] Marcas mentions that Alessio’s book, Gluten Freedom, which he co-authored with his colleague Susie Flaherty, was referred to by the Celiac Disease Foundation as “a must have,” and “an excellent reference for those with gluten related disorders.” Marcas asks Alessio about this reception to his book.

[00:31:24] Marcas mentions that the only viable treatment for individuals with celiac disease has been a gluten-free diet, with pharmaceutical companies having had little interest until recently in investigating the disease. Now there are more than 20 drug therapies in development for celiac. Marcas asks Alessio about the progress being made to develop pharmacological interventions for celiac.

[00:34:17] Ken mentions that gluten sensitivity affects more than 20 million Americans. This sensitivity is when a person reacts negatively to the gluten protein but does not test positive for celiac. Ken mentions that this condition is often underappreciated by physicians and asks Alessio to discuss gluten sensitivity and its impact.

[00:40:41] Marcas points out that celiac disease is a disorder with genetic components. A group of genes called HLADQ and DQI genes are involved in the development of the disease. About a third of the population inherits these genes, but not everyone who possesses them will develop celiac. Marcas asks Alessio to elaborate on this phenomenon.

[00:42:51] Marcas asks Alessio to talk briefly about his book Gluten Freedom.

[00:43:40] Ken asks about the experience Alessio had working with Bob Prior at MIT Press, the publisher of Gluten Freedom.

[00:47:07] Ken mentions that Alessio has expressed in the past that he does not like the term “leaky gut,” which can be offered as a diagnosis, and asks Alessio why that is.

[00:49:38] Ken mentions Alessio gave a talk in 2018 at the Institute for Functional Medicine’s annual conference titled: “Autoimmunity and the Interplay of Genes and the Environment.” Ken explains that this talk began by pointing out that medicine is still largely ignorant of certain aspects of human biology, and how and why people get sick. Ken asks Alessio to discuss the main points of this talk.

[00:52:21] Ken mentions that in researching “Gluten Freedon” that Alessio consulted with Claire Fraser who was our guest on episode 32. Ken asks Alessio how he met Claire.

[00:55:28] Marcas pivots to talk about Alessio’s current work, namely his recent project “The Celiac Disease Genomic Environmental Microbiome and Metabolomics Study.” Marcas goes on to explain that this project will follow infants from birth through childhood in an effort to better understand the many factors that contribute to the development of celiac.

[01:06:12] Ken mentions that for this study, Alessio recruited not only American families but also participants from Spain and Italy, asking what the rationale was for those populations.

[01:07:14] Marcas asks if the overarching goal of this study is to pave the way for personalized prevention of celiac disease.

[01:08:37] Marcas asks about a paper Alessio published in the American Journal of Gastroenterology titled: “Early Antibody Dynamics in a Prospective Cohort of Children At-Risk for Celiac Disease,” which aimed to identify possible serum biomarkers that could help predict celiac disease in at-risk children. Marcas asks Alessio to talk about the design of this study and its findings.

[01:10:14] Ken pivots to talk about a study Alessio published earlier this year in the Journal Pediatrics on zonulin. Ken explains that this study evolved from the observation that increased intestinal permeability appears to be a key factor in several autoimmune diseases including celiac. However, the question remains whether increased permeability of the intestines precedes disease onset or if it is a consequence of disease onset. Ken asks Alessio to touch on this study and its findings.

[01:11:41] Marcas mentions that as a pediatric gastroenterologist, Alessio also works with children on the autism spectrum, who in addition to social challenges and repetitive behaviors deal with a variety of symptoms. Marcas asks Alessio to talk about his experience working with these children.

[01:16:27] Ken mentions that when we last had Alessio on STEM-Talk, he was in the middle of renovating a 13th century monastery into the European Biomedical Research Institute of Salerno. Ken asks Alessio to give an update on this project.

[01:19:54] Marcas mentions that Alessio’s son, Stefan, has joined IHMC as a research associate. Marcas asks Alessio how Stefan is liking it here at IHMC.

[01:22:56] Marcas ends the interview asking Alessio if he will write another book.

Links:

Learn more about IHMC

STEM-Talk homepage

Ken Ford bio

Ken Ford Wikipedia page

Marcas Bamman

Alessio Fasano

Today we have Dr. Nicholas Norwitz, 28, a third-year Harvard Medical School student whose research into the applications of a ketogenic diet as metabolic medicine has attracted a significant following.

For a number of years during his youth, Nick suffered from a number of debilitating diseases, including osteoporosis, ulcerative colitis, and inflammatory bowel disease.  In today’s interview, we talk to Nick about research that led him to adopt a ketogenic diet that put him back on the road to metabolic health.

After graduating from Dartmouth College in 2018 with a degree in cellular and molecular biology, Nick attended Oxford University where he earned a Ph.D. in metabolism and nutrition. He is the author of peer-reviewed scientific papers and textbook chapters on topics including Alzheimer’s disease, cardiovascular disease, diabetes, gastrointestinal health, genetics osteology and Parkinson’s disease.

Show notes:

 [00:02:53] Marcas opens the interview mentioning that Neck grew up in Boston, and asks if it’s true that he was a very curious kid growing up.

[00:04:09] Marcas asks Nick if as a young child he always knew he wanted to be a physician and a scientist.

[00:05:40] Ken mentions that Nick was a runner in high school, and as is the case with many runners, this led to fractures. However, Ken goes on to say that these fractures did not resolve for Nick, and asks what he learned as a result.

[00:11:08] Ken asks about Nick’s eating habits in college as he loved to cook and bake.

[00:15:40] Marcas follows up, asking Nick at what point during his Ph.D. training was he admitted to palliative care.

[00:21:01] Marcas pivots to talk about the need for incorporating metabolic health into our health-care system. He mentions that Nick once said that “we live in a society where our social norms and ecosystem, with respect to health and food, are extremely dysfunctional,” and asks Nick to elaborate on this.

[00:26:16] Ken mentions a paper that Nick recently published titled, “Oreo Cookie Treatment Lowers LDL Cholesterol More Than High Intensity Statin Therapy in a Lean Mass Hyper-Responder on the Ketogenic Diet: A Curious Crossover Study.” To provide some background, Ken mentions that some people on a ketogenic or low carb diet experience a dramatic increase in LDL cholesterol. The rationale behind Nick’s paper being that if it is the removal of carbohydrates that causes this increase in LDL, adding carbohydrates back into one’s diet should bring LDL levels back down. Ken asks Nick to talk about this experiment and how he designed it.

[00:35:44] Ken mentions that the paper seems to be designed to be provocative, as simply testing carbohydrates against statins would likely have not gotten as much attention as using Oreo cookies.

[00:37:00] Marcas mentions that in the Oreo cookie vs statin experiment, Nick’s original fasted-morning LDL was 384, before dropping it with Oreos, then doing a washout before dropping it again with statins. Marcas asks Nick what his fasted-morning LDL was post washout, prior to the statin intervention.

[00:39:07] Marcas brings up Nick’s paper titled: “The Lipid Energy Model: Reimagining Lipoprotein Function in the Context of Carbohydrate Restricted Diets.” Marcas goes on to mention that the aim of the paper was to propose a mechanistic explanation for the “lean mass hyper-responder phenotype.” Marcas asks Nick to give listeners an overview of the lipid-energy model.

[00:45:18] Ken mentions that according to Nick, BMI is not a requirement for classification as a lean mass hyper-responder. Nick’s paper, however, uses BMI data. Ken mentions that he finds BMI relatively useless and asks why Nick did not use DEXA scans instead.

[00:48:52] Ken mentions that adipose tissue contains roughly 25 percent of total body cholesterol, and we know that LDL binding to adipose cell membranes is competitively inhibited by HDL. Ken asks if lean mass hyper-responders were found to have low fat mass as a defining feature, how might this effect the lipid panel in terms of LDL-C.

[00:50:50] Ken explains that the thinking regarding HDL is currently being refined, with current ideas regarding HDL all-cause mortality currently conforming to a U-shaped curve. Ken asks, with respect to lean mass hyper-responders, what sort of health risks these high HDL levels might confer.

[00:53:50] Marcas asks Nick how the lipid-energy model would apply in the population of lean people with respect to the difference between untrained individuals and highly trained athletic people, and if he can envision a study to tackle that question. Marcas goes on to ask when Nick thinks would be the best time to acquire samples in this hypothetical study, relative to bouts of exercise.

[00:57:55] Marcas mentions that the European Society of Cardiology and the European Society of Atherosclerosis came out with a consensus in 2019 on the superiority of apolipoprotein B measurement of serum cholesterol levels as an indicator of risk. Marcas goes on to mention that while apolipoprotein B was not measured in Nick’s Oreo study, his high LDL measurement was correlated with a high LDL particle count, meaning that lean-mass hyper responders might have a high apolipoprotein B and or high-particle count, which could translate to risk for cardiovascular disease. Marcas asks Nick what his thoughts are on how people on low carb diets should navigate high apolipoprotein B levels.

[01:01:09] Marcas pivots to ask about a piece that Nick wrote on a website called Stat, which is a journalistic site covering health, medicine, and life science. The piece detailed Nick’s concern going into medical school that being on the ketogenic diet would make him something of a pariah. Marcas asks how his experience in med school is now three years later, and whether or not he is in fact a pariah.

Links:

Learn more about IHMC

STEM-Talk homepage

Ken Ford bio

Ken Ford Wikipedia page

Marcas Bamman bio

Nick Norwitz bio

Dr. Vyvyane Loh returns to STEM-Talk for her second appearance to talk about atherosclerotic heart disease. Also known as ASCVD, the disease has been reported to affect 26 million people in the U.S., and annually leads two million hospitalizations and more than 400,000 deaths.

Vyvyane is a board-certified physician in obesity and internal medicine. In episode 142 of STEM-Talk, we talked to Vyvyane about her Boston-based preventative-care practice that specializes in weight management and the treatment of chronic metabolic diseases such as diabetes, hypertension and dyslipidemia.

In today’s podcast, Vyvyane and host Dr. Ken Ford talk about ASCVD as well as recent research that has shown substantial individual variability in the response to statin therapy as a way to lower cardiovascular risk. Vyvyane and Ken also discuss how the current knowledge base informing clinical practice in medicine today is far behind advances in the biological sciences, especially in the field of ASCVD.

Show notes:

 [00:03:15] Ken welcomes Vyvyane back to STEM-Talk and encourages listeners to check out Vyvyane’s first interview, episode 142. Ken goes on to mention that atherosclerotic heart disease has been reported to affect 26 million people in the U.S. and that despite the wide use of statins as a primary prevention of atherosclerotic heart disease, the effects of this treatment have been variable with regards to major adverse cardiac events. Ken asks Vyvyane for her thoughts.

[00:05:32] Ken asks Vyvyane about recent developments in atherosclerotic heart disease research, specifically in regard to the anatomical aspects of the disease-model itself.

[00:08:43] Ken follows up asking Vyvyane how the knowledge we have of glycocalyces, and the endothelial lining of the blood vessels, could affect clinical practice.

[00:12:19] Ken asks if there are any other recent updates to the anatomical model of atherosclerotic disease that people should be aware of.

[00:13:09] Ken asks Vyvyane how she would characterize the significance of the tunica intima of the coronary artery.

[00:15:25] Ken asks about the third recent anatomical highlight to blood vessels relevant to the discussion.

[00:19:19] Ken follows up, asking if this is how the vasa vasorum contributes to our understanding of the development of atherosclerosis.

[00:21:05] Ken asks Vyvyane to explain what endothelial dysfunction is and what are its downstream effects.

[00:26:09] Ken asks Vyvyane to expound on the link between atherosclerotic disease and auto-immunity.

[00:31:01] Ken asks, given the link to inflammation, if there have been any therapeutic developments made in the treatment of atherosclerotic disease.

[00:34:54] Ken asks about the vaccine that is being developed for atherosclerosis.

[00:37:53] Ken mentions that another recent development in the field is the growing appreciation for clonal hematopoiesis in atherosclerosis. Ken asks Vyvyane to explain what clonal hematopoiesis is.

[00:39:55] Ken asks Vyvyane what some actionable takeaways are from our discussion on atherosclerosis that listeners can take home with them.

[00:43:17] Ken asks Vyvyane about her passion for dance, and how much time she invests in that area of her life.

[00:48:11] Ken follows up asking Vyvyane what drives her to pursue dance so passionately.

[00:53:34] In closing the interview, Ken encourages listeners to check out Vyvyane’s podcast as well as her website.

Links:

Vyvyane Loh website

Vlmdrounds.com

Learn more about IHMC

STEM-Talk homepage

Ken Ford bio

Ken Ford Wikipedia page

Today we have Dr. Johnathan Edwards, an anesthesiologist and medical practitioner who specializes in human health and optimization. He is perhaps best known for treating mental health conditions with ketamine,  a dissociative anesthetic that is used for general anesthesia, pain relief, depression and epilepsy. John also uses ketamine to help adolescents overcome depression and suicidal ideation.

In today’s interview, we talk about his new book, “The Revolutionary Ketamine: The Safe Drug That Effectively Treats Depression and Prevents Suicide.” More Americans have died from suicide than all the wars since Vietnam. The suicide rate among 10- to-24-year-olds in this country increased 62 percent from 2007 through 2021. As John points out in today’s discussion, most people are not aware that American children between the ages of 10 and 14 are twice as likely to die from suicide than homicide.

Show notes:

[00:02:39] Dawn explains that suicide is a pressing problem in America, with more Americans dying of suicide than from all the wars since Vietnam. She also points out that police and firefighters are more likely to die from suicide than in the line of duty. John then gives an overview of ketamine and its ability to help treat depression and suicidal thoughts.

[00:06:56] Dawn pivots to mention the dark side of ketamine, including ketamine misuse and overdose.  Recent studies have reported a worldwide increase in ketamine misuse and overdoses. Back in October, Mathew Perry, one of the stars of the popular sit-com “Friends,” died from what the Los Angeles cororner described as the acute effects of ketamine. Because this was such a high-profile case, Dawn asks John to discuss the potential adverse effects of ketamine.

[00:13:03] Ken mentions a 2022 study in the American Journal of Drug and Alcohol Abuse that looked at ketamine overdoses and deaths. The study found no cases of overdose or death from ketamine used in a clinical setting as therapy for depression. Ken asks if there is anything John would like to add about ketamine and safety.

[00:13:059] Dawn shifts to talk about John’s background, mentioning that he grew up riding dirt bikes and eventually raced bikes professionally.

[00:15:18] Ken asks John to share his story of how a junior college professor sparked his interest in science.

[00:17:49] Dawn mentions that John jumped around from Eastern Virginia Medical School, to the University of Reno, to the University of Utah, at which point it looked as though he was heading for a career in internal medicine. Dawn asks why John changed his mind and decided not to pursue that career path.

[00:19:40] Dawn asks John what led him to the University of South Florida.

[00:20:18] Ken asks John about another career shift that came about as the result of a suggestion from one of John’s professors.

[00:21:42] Dawn asks about John’s motivation to move to Las Vegas to be close to his father.

[00:22:59] Dawn asks John to explain what motivated him and his wife to move to France after their daughter turned five.

[00:24:55] Dawn asks John to talk about the transition of ketamine from anesthetic to antidepressant.

[00:28:16] In his book on ketamine, John writes about how the benefits of supervised psychedelic therapy can be broken down into four effects. Ken asks John to briefly explain each of these effects.

[00:31:39] Dawn asks John to explain how ketamine manipulates the function of brain receptors as an antagonist and agonist.

[00:33:40] Dawn mentions that some people do not believe that ketamine functions as a classic psychedelic like psylocibin or LSD. She asks John if he agrees.

[00:35:54] Ken mentions a recent STEM-Talk interview with Mark Mattson discussing glutamate. In Mark’s book, “Sculptor and Destroyer: Tales of Glutamate,” he points out that ketamine’s highest interactions are with glutamate, and this affinity has been shown to alleviate depression and schizophrenia. Ken asks John to discuss the significance of ketamine with respect to its ability to increase glutamate.

[00:38:45] Dawn asks John to talk about MDMA, which is another non-classical psychedelic that has medicinal properties, particularly in the treatment of PTSD.

[00:40:48] Ken brings up STEM-Talk’s interview with Rachel Yehuda in episode 101, whose research has revolutionized our understanding of PTSD. In John’s book he mentions that we have historically not been very good at the complex task of treating PTSD, which Rachel also echoed in her interview. Ken explains that a key problem, historically, has been the stigma associated with psychedelics, and he asks John if he thinks that this stigma is lessening in light of the numerous positive findings on the use of psychedelics to treat PTSD.

[00:44:34] Ken explains that inflammation and suicide are closely linked, and while the mechanisms whereby ketamine acts as an anti-suicidal drug are somewhat unclear, there is emerging evidence that ketamine is an anti-inflammatory agent. Ken asks John to talk about this.

[00:47:11] Ken asks what John’s take is on the evidence that whales might also engage in suicidal behavior.

[00:49:35] Dawn asks John to talk about the important point that ketamine and other medications are far less effective in treating mental health disorders when not coupled with psychotherapy.

[00:52:07] Ken explains that following the institution of COVID lockdowns, drug overdoses in America increased substantially from previous years. Ken asks John to give his insight on this increase.

[00:55:07] Ken asks John about those individuals who should not be on ketamine, mentioning people suffering from mania and schizophrenia, and asks if there are other groups that should steer clear of ketamine.

[00:56:57] Ken asks if ketamine is effective in treating chronic pain.

[00:58:38] Dawn closes the interview asking about John’s experience traveling the world for the Dakar Rally, which is an off-road endurance event. Dawn also mentions that the rally will be the topic of John’s next book.

Links:

Johnathan Edwards bio

Learn more about IHMC

STEM-Talk homepage

Ken Ford bio

Ken Ford Wikipedia page

Dawn Kernagis bio